Clinical significance of large rearrangements in BRCA1 and BRCA2

Cancer

Volumn 118, Issue 21, 2012, Pages 5210-5216

  Judkins, Thaddeus ^a   Rosenthal, Eric ^a   Arnell, Christopher ^a   Burbidge, Lynn Anne ^a   Geary, Wade ^a   Barrus, Toby ^a   Schoenberger, Jeremy ^a   Trost, Jeffrey ^a   Wenstrup, Richard J ^a   Roa, Benjamin B ^a  

^a Myriad Genetic Laboratories   (United States)

Author keywords

BRCA1 gene; BRCA2 gene; gene rearrangement; hereditary breast and ovarian cancer syndrome; mutation frequency

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; DNA;

ADULT; AMERICAN INDIAN; ARTICLE; ASHKENAZI; ASIAN; BASE PAIRING; BREAST CANCER; CAUCASIAN; DATA ANALYSIS; DNA FLANKING REGION; ETHNIC GROUP; FEMALE; GENE DELETION; GENE DUPLICATION; GENE FREQUENCY; GENE MUTATION; GENE REARRANGEMENT; GENETIC ANALYSIS; HEALTH CARE PERSONNEL; HIGH RISK PATIENT; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; MEDICAL HISTORY; MULTIPLEX POLYMERASE CHAIN REACTION; MUTATIONAL ANALYSIS; NEGRO; OVARY CANCER; PATIENT REFERRAL; PENETRANCE; PREVALENCE; PRIORITY JOURNAL; PROBABILITY; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; SEQUENCE ANALYSIS; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; HUMANS; MUTATION; OVARIAN NEOPLASMS; RISK FACTORS; SEQUENCE ANALYSIS, DNA; TRANSLOCATION, GENETIC;

EID: 84867884099     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27556     Document Type: Article

References (22)

1. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998; 62: 676-689.
2. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE,. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet. 1994; 343: 692-695.
3. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003; 72: 1117-1130.
4. Liede A, Karlan BY, Narod SA,. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol. 2004; 22: 735-742.
5. Antoniou AC, Gayther SA, Stratton JF, Ponder BA, Easton DF,. Risk models for familial ovarian and breast cancer. Genet Epidemiol. 2000; 18: 173-190.
6. Anglian Breast Cancer Study Group. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Br J Cancer. 2000; 83: 1301-1308.
7. Nathanson KL, Domchek SM,. Therapeutic approaches for women predisposed to breast cancer. Annu Rev Med. 2011; 62: 295-306.
8. National Comprehensive Cancer Network. NCCN Practice Guidelines in Oncology. Genetic/Familial High-Risk Assessment: Breast and Ovarian, version 1; 2011.
9. Armour JA, Barton DE, Cockburn DJ, Taylor GR,. The detection of large deletions or duplications in genomic DNA. Hum Mutat. 2002; 20: 325-337.
10. Lim BC, Lee S, Shin JY, et al. Genetic diagnosis of Duchenne and Becker muscular dystrophy using next-generation sequencing technology: comprehensive mutational search in a single platform. J Med Genet. 2011; 48: 731-736.
11. Brownstein Z, Friedman LM, Shahin H, et al. Targeted genomic capture and massively parallel sequencing to identify genes for hereditary hearing loss in middle eastern families. Genome Biol. 2011; 12: R89.
12. Walsh T, Casadei S, Lee MK, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A. 2011; 108: 18032-18037.
13. Ewald IP, Ribeiro PL, Palmero EI, Cossio SL, Giugliani R, Ashton-Prolla P,. Genomic rearrangements in BRCA1 and BRCA2: A literature review. Genet Mol Biol. 2009; 32: 437-446.
14. Walsh T, Casadei S, Coats KH, et al. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA. 2006; 295: 1379-1388.
15. Hendrickson BC, Judkins T, Ward BD, et al. Prevalence of five previously reported and recurrent BRCA1 genetic rearrangement mutations in 20,000 patients from hereditary breast/ovarian cancer families. Genes Chromosomes Cancer. 2005; 43: 309-313.
16. Myriad Genetic Laboratories, Incorporated. BRACAnalysis Technical Specifications. http://www.myriad.com/lib/technical-specifications/BRACAnalysis- Technical-Specifications.pdf. Updated: October 2011. Accessed January 11, 2012.
17. Kazazian HH Jr, Boehm CD, Seltzer WK,; ACMG Laboratory Practice Committee Working Group. ACMG recommendations for standards for interpretation of sequence variations. Genet Med. 2000; 2: 302-303.
18. Minitab Incorporated. Minitab 15 Statistical Software [computer program]. State College, PA: Minitab; 2007.
19. Sluiter MD, van Rensburg EJ,. Large genomic rearrangements of the BRCA1 and BRCA2 genes: review of the literature and report of a novel BRCA1 mutation. Breast Cancer Res Treat. 2011; 125: 325-349.
20. Weitzel JN, Lagos VI, Herzog JS, et al. Evidence for common ancestral origin of a recurring BRCA1 genomic rearrangement identified in high-risk Hispanic families. Cancer Epidemiol Biomarkers Prev. 2007; 16: 1615-1620.
21. Mazoyer S,. Genomic rearrangements in the BRCA1 and BRCA2 genes. Hum Mutat. 2005; 25: 415-422.
22. Torres D, Rashid MU, Seidel-Renkert A, Weitzel JN, Briceno I, Hamann U,. Absence of the BRCA1 del (exons 9-12) mutation in breast/ovarian cancer families outside of Mexican Hispanics. Breast Cancer Res Treat. 2009; 117: 679-681.